<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00913913</url>
  </required_header>
  <id_info>
    <org_study_id>D0708</org_study_id>
    <secondary_id>R01CA095648</secondary_id>
    <nct_id>NCT00913913</nct_id>
  </id_info>
  <brief_title>Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients</brief_title>
  <official_title>A Phase II Study of VEGF Blockade With Bevacizumab Combined With Autologous Tumor/Dendritic Cell Vaccine (DC Vaccine), Interleukin-2 (IL-2) and Interferon-α-2b (IFNα-2b) in Patients With Metastatic Renal Cell Carcinoma (RCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immune therapies, such as a IL-2, for metastatic renal cell carcinoma (mRCC) are designed to
      mobilize immune effector cells that recognize and destroy cancer. The investigators have
      recently observed a 50% objective response rate (16% CR) in mRCC patients treated with
      autologous tumor lysate -dendritic cell (DC)-vaccine, IL-2 and interferon alfa (IFN). New
      agents inhibiting vascular endothelial growth factor (VEGF) pathways have demonstrated
      significant benefit in mRCC patients as well, but rarely induce CRs. High blood VEGF is
      associated with poor response to IL-2 and can cause tumor specific immune dysregulation. To
      test whether complementary mechanisms of immune activation and disruption of regulatory
      pathways enhance outcome the investigators plan to treat 24 mRCC patients in a phase II trial
      using bevacizumab, DC vaccine, IL-2, and IFN. Observations from this project will be used in
      the development of novel cancer therapies which, if successful, will decrease the burden of
      cancer on the public.

      The investigators propose to determine 1) the objective clinical response rate to treatment
      and progression free survival, 2) the clinical and autoimmune related toxicity profile of
      therapy, and 3) the treatment related tumor-specific immune response and the relationship of
      tumor-specific immune response and objective clinical response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All eligible patients will receive a total of five treatment weeks, each consisting of
      approximately 5 days. Prior to therapy, patients will undergo apheresis for DC preparation.
      DC-Tumor vaccines will be frozen in 90% pooled human AB serum/ 10% DMSO to be used for
      treatment Patients will be dosed with bevacizumab (10mg/kg, Genentech) intravenously every
      two weeks beginning four weeks prior to the first vaccine. Each treatment week includes
      ultrasound guided intranodal DC-vaccine injection (1 X 107 cells/1mL), followed by 5 days of
      continuous intravenous infusion of IL-2 (18 MiU/m2, Novartis), and three subcutaneous
      injections of IFNa-2b (6 MiU, Schering -Plough Corp.) (every other day). The first two
      treatment weeks, the induction phase, will be separated by a 9 day rest. Three additional
      treatment weeks, the maintenance phase, will be separated by 23 rest days.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual not allowing site to meeting statistical endpoints
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>median progression free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Characterize the Number of Participants With Clinical and Autoimune Related Toxicity of Treatment</measure>
    <time_frame>5 years</time_frame>
    <description>To characterize the clinical and autoimmune related toxicity profile of the combined treatment regimen using CTCAE 3. Toxicity reported are those expected from high dose IL-2 and were not considered adverse events.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Measure of Percent of CD4 and CD8 Lymphocyte Subsets</measure>
    <time_frame>Baseline, day 28, day 70</time_frame>
    <description>percent of CD4 and CD8 positive lymphocyte subsets</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Response</measure>
    <time_frame>Day 70</time_frame>
    <description>clinical response by RECIST 1.1</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Metastatic Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>bevacizumab,IL-2, IFN, DC vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be dosed with bevacizumab (10mg/kg) intravenously every two weeks beginning four weeks prior to the first vaccine. Each treatment week includes ultrasound guided intranodal DC-vaccine injection (1 X 107 cells/1mL), followed by 5 days of continuous intravenous infusion of IL-2 (18 MiU/m2), and three subcutaneous injections of IFNa-2b (6 MiU) (every other day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DC vaccine</intervention_name>
    <description>DC Vaccine therapy 10E7 intranodally every cycle</description>
    <arm_group_label>bevacizumab,IL-2, IFN, DC vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab 10mg/kg iv every 2 weeks</description>
    <arm_group_label>bevacizumab,IL-2, IFN, DC vaccine</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IL-2</intervention_name>
    <description>IL-2 18 MiU/m2 CI 5 days</description>
    <arm_group_label>bevacizumab,IL-2, IFN, DC vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IFN</intervention_name>
    <description>IFN 6 MiU subc TIW</description>
    <arm_group_label>bevacizumab,IL-2, IFN, DC vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed metastatic renal cell carcinoma with measurable disease.

          2. Adequate tumor tissue properly stored and available to produce lysate for a minimum of
             three vaccine preparations.

          3. Patients must be at least 4 weeks from their last therapy (tyrosine kinase inhibitors,
             immunotherapy, radiation, surgery or chemotherapy (6 weeks for nitrosureas) and
             recovered from all ill effects.

          4. Have measurable disease.

          5. Patients must be at least 4 weeks from major surgery, 1 week from minor surgery, and
             recovered from all ill effects.

          6. Karnofsky Performance Status ≥80%.

          7. Adequate end organ function:

          8. Women should not be lactating and, if of childbearing age, have a negative pregnancy
             test within two weeks of entry to the study.

          9. Appropriate contraception in both genders.

         10. The patient must be competent and have signed informed consent.

         11. Patients may have received one prior therapy with targeted therapies (e.g. sorafenib
             and sunitinib).

        Exclusion Criteria:

          1. Patients who have previously received bevacizumab or IL-2 are not eligible.

          2. Concomitant second malignancy except for non-melanoma skin cancer, and non-invasive
             cancer such as cervical CIS, superficial bladder cancer without local recurrence or
             breast CIS.

          3. In patients with a prior history of invasive malignancy, less than five years in
             complete remission.

          4. Positive serology for HIV, hepatitis B or hepatitis C which should be confirmed with
             antigenemia.

          5. Significant co-morbid illness such as uncontrolled diabetes or active infection that
             would preclude treatment on this regimen.

          6. Use of corticosteroids or other immunosuppression (if patient had been taking
             steroids, at least 2 weeks must have passed since the last dose). Inhaled steroids &gt;
             1000mcg beclomethasone per day or its equivalent.

          7. History of inflammatory bowel disease or other serious autoimmune disease. (Not
             including thyroiditis and rheumatoid arthritis).

          8. Patients with organ allografts.

          9. Uncontrolled hypertension (BP &gt;150/100 mmHg).

         10. Proteinuria dipstick &gt; 3+ or &gt; 2gm/24 hours, or a urine protein:creatinine ratio &gt; 1.0
             at screening.

         11. Major surgery, open biopsy, significant traumatic injury within 28 days of starting
             treatment or anticipation of need for major surgical procedure during the course of
             the study.

         12. Minor surgical procedures, fine needle aspirations or core biopsies within 7 days
             prior to starting treatment. Central venous catheter placements are permitted.

         13. History of abdominal fistula, gastrointestinal perforation, or intrabdominal abscess
             within 6 months prior to starting treatment.

         14. Serious, non-healing wound, ulcer, or bone fracture.

         15. History of tumor-related or other serious hemorrhage, bleeding diathesis, or
             underlying coagulopathy.

         16. History of deep venous thrombosis, or other thrombotic event within the past six
             months or clinically significant peripheral vascular disease.

         17. Inability to comply with study and/or follow-up procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc S Ernstoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ernstoff MS, Crocenzi TS, Seigne JD, Crosby NA, Cole BF, Fisher JL, Uhlenhake JC, Mellinger D, Foster C, Farnham CJ, Mackay K, Szczepiorkowski ZM, Webber SM, Schned AR, Harris RD, Barth RJ Jr, Heaney JA, Noelle RJ. Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):733s-740s. Review.</citation>
    <PMID>17255302</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2009</study_first_submitted>
  <study_first_submitted_qc>June 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2009</study_first_posted>
  <results_first_submitted>February 19, 2014</results_first_submitted>
  <results_first_submitted_qc>October 28, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 1, 2015</results_first_posted>
  <last_update_submitted>October 28, 2015</last_update_submitted>
  <last_update_submitted_qc>October 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Cell Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bevacizumab,IL-2, IFN, DC Vaccine</title>
          <description>Patients will be dosed with bevacizumab (10mg/kg) intravenously every two weeks beginning four weeks prior to the first vaccine. Each treatment week includes ultrasound guided intranodal DC-vaccine injection (1 X 107 cells/1mL), followed by 5 days of continuous intravenous infusion of IL-2 (18 MiU/m2), and three subcutaneous injections of IFNa-2b (6 MiU) (every other day)
DC vaccine: DC Vaccine therapy 10E7 intranodally every cycle
Bevacizumab: Bevacizumab 10mg/kg iv every 2 weeks
IL-2: IL-2 18 MiU/m2 CI 5 days
IFN: IFN 6 MiU subc TIW</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Number was the actual number of patients who signed consent and received treatment on study.</population>
      <group_list>
        <group group_id="B1">
          <title>Bevacizumab,IL-2, IFN, DC Vaccine</title>
          <description>Patients will be dosed with bevacizumab (10mg/kg) intravenously every two weeks beginning four weeks prior to the first vaccine. Each treatment week includes ultrasound guided intranodal DC-vaccine injection (1 X 107 cells/1mL), followed by 5 days of continuous intravenous infusion of IL-2 (18 MiU/m2), and three subcutaneous injections of IFNa-2b (6 MiU) (every other day)
DC vaccine: DC Vaccine therapy 10E7 intranodally every cycle
Bevacizumab: Bevacizumab 10mg/kg iv every 2 weeks
IL-2: IL-2 18 MiU/m2 CI 5 days
IFN: IFN 6 MiU subc TIW</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age is the mean of the age of the 8 patients at time of consent for study participation.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="50" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival</title>
        <description>median progression free survival</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab,IL-2, IFN, DC Vaccine</title>
            <description>Patients will be dosed with bevacizumab (10mg/kg) intravenously every two weeks beginning four weeks prior to the first vaccine. Each treatment week includes ultrasound guided intranodal DC-vaccine injection (1 X 107 cells/1mL), followed by 5 days of continuous intravenous infusion of IL-2 (18 MiU/m2), and three subcutaneous injections of IFNa-2b (6 MiU) (every other day)
DC vaccine: DC Vaccine therapy 10E7 intranodally every cycle
Bevacizumab: Bevacizumab 10mg/kg iv every 2 weeks
IL-2: IL-2 18 MiU/m2 CI 5 days
IFN: IFN 6 MiU subc TIW</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>median progression free survival</description>
          <units>DAYS</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="340" lower_limit="73" upper_limit="1582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Characterize the Number of Participants With Clinical and Autoimune Related Toxicity of Treatment</title>
        <description>To characterize the clinical and autoimmune related toxicity profile of the combined treatment regimen using CTCAE 3. Toxicity reported are those expected from high dose IL-2 and were not considered adverse events.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab,IL-2, IFN, DC Vaccine</title>
            <description>Patients will be dosed with bevacizumab (10mg/kg) intravenously every two weeks beginning four weeks prior to the first vaccine. Each treatment week includes ultrasound guided intranodal DC-vaccine injection (1 X 107 cells/1mL), followed by 5 days of continuous intravenous infusion of IL-2 (18 MiU/m2), and three subcutaneous injections of IFNa-2b (6 MiU) (every other day)
DC vaccine: DC Vaccine therapy 10E7 intranodally every cycle
Bevacizumab: Bevacizumab 10mg/kg iv every 2 weeks
IL-2: IL-2 18 MiU/m2 CI 5 days
IFN: IFN 6 MiU subc TIW</description>
          </group>
        </group_list>
        <measure>
          <title>To Characterize the Number of Participants With Clinical and Autoimune Related Toxicity of Treatment</title>
          <description>To characterize the clinical and autoimmune related toxicity profile of the combined treatment regimen using CTCAE 3. Toxicity reported are those expected from high dose IL-2 and were not considered adverse events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Measure of Percent of CD4 and CD8 Lymphocyte Subsets</title>
        <description>percent of CD4 and CD8 positive lymphocyte subsets</description>
        <time_frame>Baseline, day 28, day 70</time_frame>
        <population>Peripheral blood lymphocyte subsets: 5 subjects at baseline and same 5 at day 70. 6 subjects analyzed at day 28</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab,IL-2, IFN, DC Vaccine</title>
            <description>Patients will be dosed with bevacizumab (10mg/kg) intravenously every two weeks beginning four weeks prior to the first vaccine. Each treatment week includes ultrasound guided intranodal DC-vaccine injection (1 X 107 cells/1mL), followed by 5 days of continuous intravenous infusion of IL-2 (18 MiU/m2), and three subcutaneous injections of IFNa-2b (6 MiU) (every other day)
DC vaccine: DC Vaccine therapy 10E7 intranodally every cycle
Bevacizumab: Bevacizumab 10mg/kg iv every 2 weeks
IL-2: IL-2 18 MiU/m2 CI 5 days
IFN: IFN 6 MiU subc TIW</description>
          </group>
        </group_list>
        <measure>
          <title>Measure of Percent of CD4 and CD8 Lymphocyte Subsets</title>
          <description>percent of CD4 and CD8 positive lymphocyte subsets</description>
          <population>Peripheral blood lymphocyte subsets: 5 subjects at baseline and same 5 at day 70. 6 subjects analyzed at day 28</population>
          <units>percentage of total lymphocytes</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4 Central memory: baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" lower_limit="0.21" upper_limit="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 Central memory: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" lower_limit="0.80" upper_limit="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 Central memory: Day 70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" lower_limit="0.14" upper_limit="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 Central memory: baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" lower_limit="0.32" upper_limit="5.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 Central memory: day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.74" lower_limit="2.49" upper_limit="7.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 Central memory: day 70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.76" lower_limit="0.18" upper_limit="9.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinical Response</title>
        <description>clinical response by RECIST 1.1</description>
        <time_frame>Day 70</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab,IL-2, IFN, DC Vaccine</title>
            <description>Patients will be dosed with bevacizumab (10mg/kg) intravenously every two weeks beginning four weeks prior to the first vaccine. Each treatment week includes ultrasound guided intranodal DC-vaccine injection (1 X 107 cells/1mL), followed by 5 days of continuous intravenous infusion of IL-2 (18 MiU/m2), and three subcutaneous injections of IFNa-2b (6 MiU) (every other day)
DC vaccine: DC Vaccine therapy 10E7 intranodally every cycle
Bevacizumab: Bevacizumab 10mg/kg iv every 2 weeks
IL-2: IL-2 18 MiU/m2 CI 5 days
IFN: IFN 6 MiU subc TIW</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response</title>
          <description>clinical response by RECIST 1.1</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From time patient first dosed with any study specific medications to end of study. Subjects were evaluated until progression. The median time of follow up was 340 days with a range from 73 to 1582 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bevacizumab,IL-2, IFN, DC Vaccine</title>
          <description>Patients will be dosed with bevacizumab (10mg/kg) intravenously every two weeks beginning four weeks prior to the first vaccine. Each treatment week includes ultrasound guided intranodal DC-vaccine injection (1 X 107 cells/1mL), followed by 5 days of continuous intravenous infusion of IL-2 (18 MiU/m2), and three subcutaneous injections of IFNa-2b (6 MiU) (every other day)
DC vaccine: DC Vaccine therapy 10E7 intranodally every cycle
Bevacizumab: Bevacizumab 10mg/kg iv every 2 weeks
IL-2: IL-2 18 MiU/m2 CI 5 days
IFN: IFN 6 MiU subc TIW</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>hyperbilirubinemia</sub_title>
                <description>grade 4 hepatobiliary dysfunction related to IL-2 therapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Liver dysfunction/Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study closed early due to difficulty enrolling patients with enrollment limited due to new competing therapies. Though enrollment numbers per statistical design were not met, the primary objective may still be reviewed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Marc Ernstoff</name_or_title>
      <organization>Dartmouth-Hitchcock Medical Center</organization>
      <phone>603-650-5534</phone>
      <email>marc.s.ernstoff@hitchcock.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

